Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

@article{Thomas2011TargetingLM,
  title={Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis},
  author={Saskia Thomas and Daniel C. Baumgart},
  journal={Inflammopharmacology},
  year={2011},
  volume={20},
  pages={1-18}
}
Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent unmet need for novel treatments. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. We discuss the… Expand
Targeting Integrins and Adhesion Molecules to Combat Inflammatory Bowel Disease
TLDR
This article summarizes the recent data on the use of integrin-targeting and adhesion molecule–targeting therapeutics to attenuate the detrimental inflammatory response in inflammatory bowel disease. Expand
Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
TLDR
The immunology of the gut and the mechanism of action these emerging therapies for IBD are reviewed and the positioning of therapies and potential alterations to therapeutic algorithms as new medications emerge are discussed. Expand
New targets for mucosal healing and therapy in inflammatory bowel diseases
TLDR
New approaches for achieving mucosal healing and blockade of T-cell homing via the integrins α4β7 and the addressin mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) emerges as a promising new approach for IBD therapy. Expand
Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease.
TLDR
Looking at published literatures, it is found that the observed discrepancies stem from many aspects: the expression level of CX3CR1, the confounding dendritic cell subsets and most importantly, the different colitis stages and subtypes, which means that CX 3CR1 targeting strategy could be powerful weapon in fighting against colitis, but at the same time, the precise etiological and pathological mechanisms should be cautiously examined concerning the appropriate usage of C X3CR 1 targeted therapy. Expand
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease
TLDR
The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial and seems to hold promise in the treatment of gut inflammation. Expand
Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease
TLDR
It is suggested that a reduced recruitment of naïve T- Helper cells and increased frequency of T-helper cells with lymph node homing marker expression reflect mucosal healing in IBD. Expand
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update
TLDR
Preliminary data show that anti-MAdCAM, anti-β7 and anti-integrin receptor agents are not all effective in IBD, which opens new perspectives on clinical management of IBD and new directions in understanding the role of adhesion molecules and leukocyte recruitment both in CD and UC. Expand
β7 Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25hiFoxP3+ Regulatory T Cells
TLDR
Loss of β7-dependent Treg homing to gut-associated lymphoid tissues combined with loss of intrinsic Treg function exacerbated intestinal inflammation, suggesting that IBD patients with reduced CD25hiFoxP3+ Treg numbers or function or lack of interleukin 10 could be at risk for failure of α4β7 blocking therapy. Expand
The Role of Polymorphonuclear Leukocyte Trafficking in the Perpetuation of Inflammation During Inflammatory Bowel Disease
TLDR
This review highlights the multifactorial role of PMN egress into the intestinal mucosa in the pathogenesis of IBD because it represents an important area of research with therapeutic implications for the amelioration of the symptoms associated with IBD. Expand
Novel inhibitors of leukocyte transendothelial migration.
TLDR
In vivo, compound 12 exhibited significant therapeutic effects in inflammatory bowel disease (IBD)/Crohn's disease, multiple sclerosis, fatty liver disease, and rheumatoid arthritis models, and a detailed acute and chronic toxicity profile of the lead compound in vivo did not reveal any toxic effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 146 REFERENCES
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin
TLDR
Clinical data for a humanized monoclonal antibody against α4 Integrin, natalizumab, is discussed, which is the first α4 integrin antagonist in a new class of biotechnology agents referred to as selective adhesion molecule inhibitors, which hold great potential for suppressing the cycle of leukocyte infiltration and activation, and thereby, for ameliorating chronic inflammation. Expand
Inflammatory bowel disease: cause and immunobiology
TLDR
How environmental factors, infectious microbes, ethnic origin, genetic susceptibility, and a dysregulated immune system can result in mucosal inflammation are discussed. Expand
Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease.
TLDR
The different families of relevant adhesion molecules that participate in the coordinated recruitment of leukocytes into inflamed tissue are described and then discussed in terms of the pathophysiological alterations observed in selected experimental models of gastrointestinal disease. Expand
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.
TLDR
It is found that human MAdCAM-1, as in the mouse, is expressed in a tissue-selective manner and may be a relevant tissue-specific therapeutic target for the modulation of inflammatory bowel disease activity. Expand
In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells.
TLDR
It is suggested that increased expression of the adhesion molecules in IBD promotes the recruitment of granulocytes and lymphocytes through blood vessels and the cell interaction between lymphocytes-antigen presenting cells or among lymphocytes, thereby sustaining the immuno-inflammatory process in I BD. Expand
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
TLDR
The favourable short-term safety profile and preliminary efficacy findings for PF-00547,659 in this first-in-human study pave the way for further investigation in larger trials, to establish the role of PF-00928681 in ulcerative colitis treatment. Expand
Expression of vascular adhesion molecules in inflammatory bowel disease.
TLDR
ELAM-1 is expressed on colonic endothelial surfaces in association with inflammation and may play an important role in facilitating leukocyte migration into sites of active IBD involvement. Expand
Inflammatory bowel disease: clinical aspects and established and evolving therapies
TLDR
The current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management are discussed, and diagnostic and therapeutic algorithms are provided. Expand
Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.
TLDR
The adhesive interactions mediated by alpha 4 beta 7 and MAdCAM are intimately involved in leukocyte recruitment to gut in chronic inflammatory disease and may be relevant therapeutic targets for patients with inflammatory bowel disease. Expand
VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice
TLDR
VCAM-1 plays a central role in leukocyte recruitment in colitis and blockade of this adhesion molecule has higher therapeutic effect than immunoneutralization of ICAM- 1 or MAdCAM-2 in this experimental model. Expand
...
1
2
3
4
5
...